Please ensure Javascript is enabled for purposes of website accessibility

Gilead's Remdesivir Shows Promise Against COVID-19 in Sneak Peek at Clinical Trial Data

By Keith Speights – Apr 17, 2020 at 10:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

But it's too early to draw any firm conclusions from what is still anecdotal data.

Healthcare industry news website STAT reported late Thursday that early data from a clinical trial testing Gilead Sciences' (GILD -2.19%) drug remdesivir as a treatment for COVID-19 appear to be very promising. STAT obtained videoconference footage from a meeting with University of Chicago faculty involved in a late-stage study of the antiviral drug.

Of 125 patients enrolled in that section of the larger study, 113 had severe cases of COVID-19. STAT's article stated that nearly all of the patients treated with remdesivir at University of Chicago Medicine had been discharged from the hospital, and only two had died. The report fueled a big stock market jump in after-hours trading Thursday and before the bell Friday, with shares of Gilead Sciences soaring by a double-digit percentage.

Remdesivir pill

Image source: Getty Images.

No results for late-stage clinical studies of remdesivir in treating COVID-19 have been officially released by Gilead or any other party. The information reported by STAT is only anecdotal at this point. The University of Chicago said in a statement to STAT that "drawing any conclusions at this point is premature and scientifically unsound."

However, that preliminary information certainly appears to be encouraging. In the video obtained by STAT, Kathleen Mullane, who is leading the remdesivir studies at the university, said that most patients with severe COVID-19 were discharged within six days. 

Gilead Sciences expects to report preliminary data from its late-stage study of remdesivir in patients with severe COVID-19 by the end of April. The biotech should also report results in May from another late-stage study in progress evaluating the drug in patients with more moderate symptoms.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.69 (-2.19%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.